Background Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small…
Read More
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced today that it will present a…
Lead investors Varian and OrbiMed, are joined by Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital and all existing investors…
BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,…
BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019- Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today…
Hamilton, ON – Full Time Research Scientist – Chemistry Fusion Pharmaceuticals Inc. is a clinical stage radiopharmaceutical company developing Targeted…
Boston, MA – Full Time Reporting to the SVP BD and US Operations, this individual will focus on Business Development…
